Literature DB >> 20660181

Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop.

Lance Ching1, Leonidas Stamatatos.   

Abstract

HIV-1 gp140 envelope immunogens express conserved epitopes that are targeted by broadly cross-reactive neutralizing antibodies, but they fail to elicit similar antibodies upon immunization. The poor immunogenicity of conserved epitopes on gp140 could be linked to the high immunogenicity of variable Env regions on such constructs. Previous studies have shown that the first hypervariable region (V1 loop) is immunogenic on soluble gp140s but elicits type-specific antibodies. To address issues related to the high immunogenicity of the V1 loop, two conceptually opposite approaches were tested. In the first approach, we eliminated the V1 loop from our gp140 construct and examined how V1 deletion altered the immunogenic properties of other Env regions. In the second approach, we took advantage of the high immunogenicity of the V1 loop and engrafted four diverse V1 loops onto a common gp140 Env "scaffold." These four scaffolds were used as a cocktail of immunogens to elicit diverse anti-V1 antibodies, under the hypothesis that eliciting diverse anti-V1 antibodies would expand the neutralizing breadth of immune sera. Our study indicates that three of four heterologous V1 loops were immunogenic on the common Env backbone "scaffold," but heterologous anti-V1 neutralizing responses were observed in only one case. Both types of V1 modification dampened the immunogenicity of the V3 loop, differentially altered the immunogenicity of the transmembrane gp41 subunit, and altered the relative immunogenicities of unknown Env regions, including potentially the CD4-binding site (CD4-bs) and trimer-specific targets, which elicited cross-reactive neutralizing antibodies but of limited breadth.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660181      PMCID: PMC2937763          DOI: 10.1128/JVI.00868-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis.

Authors:  Marie Pancera; Jacob Lebowitz; Arne Schön; Ping Zhu; Ernesto Freire; Peter D Kwong; Kenneth H Roux; Joseph Sodroski; Richard Wyatt
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 2.  Improving on nature: focusing the immune response on the V3 loop.

Authors:  Susan Zolla-Pazner
Journal:  Hum Antibodies       Date:  2005

3.  Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope.

Authors:  Lan Wu; Zhi-Yong Yang; Ling Xu; Brent Welcher; Sarah Winfrey; Yiming Shao; John R Mascola; Gary J Nabel
Journal:  Vaccine       Date:  2006-04-18       Impact factor: 3.641

4.  Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity.

Authors:  Barna Dey; Marie Pancera; Krisha Svehla; Yuuei Shu; Shi-Hua Xiang; Jeffrey Vainshtein; Yuxing Li; Joseph Sodroski; Peter D Kwong; John R Mascola; Richard Wyatt
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

5.  Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.

Authors:  Y Li; K Svehla; N L Mathy; G Voss; J R Mascola; R Wyatt
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

6.  Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Authors:  Simon Beddows; Norbert Schülke; Marc Kirschner; Kelly Barnes; Michael Franti; Elizabeth Michael; Thomas Ketas; Rogier W Sanders; Paul J Maddon; William C Olson; John P Moore
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

7.  Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.

Authors:  Nina R Derby; Zane Kraft; Elaine Kan; Emma T Crooks; Susan W Barnett; Indresh K Srivastava; James M Binley; Leonidas Stamatatos
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

8.  Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.

Authors:  Miroslaw K Gorny; Leonidas Stamatatos; Barbara Volsky; Kathy Revesz; Constance Williams; Xiao-Hong Wang; Sandra Cohen; Robert Staudinger; Susan Zolla-Pazner
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

9.  Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.

Authors:  Amandeep K Dhillon; Helen Donners; Ralph Pantophlet; Welkin E Johnson; Julie M Decker; George M Shaw; Fang-Hua Lee; Douglas D Richman; Robert W Doms; Guido Vanham; Dennis R Burton
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

10.  A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

Authors:  Simon Beddows; Michael Franti; Antu K Dey; Marc Kirschner; Sai Prasad N Iyer; Danielle C Fisch; Thomas Ketas; Eloisa Yuste; Ronald C Desrosiers; Per Johan Klasse; Paul J Maddon; William C Olson; John P Moore
Journal:  Virology       Date:  2006-11-28       Impact factor: 3.616

View more
  12 in total

1.  Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.

Authors:  Yu Feng; Krisha McKee; Karen Tran; Sijy O'Dell; Stephen D Schmidt; Adhuna Phogat; Mattias N Forsell; Gunilla B Karlsson Hedestam; John R Mascola; Richard T Wyatt
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

2.  HIV-1 envelope glycoprotein trimer immunogenicity elicited in the presence of human CD4 alters the neutralization profile.

Authors:  Mattias N E Forsell; Krisha McKee; Yu Feng; John R Mascola; Richard T Wyatt
Journal:  AIDS Res Hum Retroviruses       Date:  2014-11       Impact factor: 2.205

3.  Noninvasive follow-up of simian immunodeficiency virus infection in wild-living nonhabituated western lowland gorillas in Cameroon.

Authors:  Lucie Etienne; Sabrina Locatelli; Ahidjo Ayouba; Amandine Esteban; Christelle Butel; Florian Liegeois; Avelin Aghokeng; Eric Delaporte; Eitel Mpoudi Ngole; Martine Peeters
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

4.  Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.

Authors:  George Sellhorn; Zane Kraft; Zachary Caldwell; Katharine Ellingson; Christine Mineart; Michael S Seaman; David C Montefiori; Eliza Lagerquist; Leonidas Stamatatos
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

5.  Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies.

Authors:  Marit J van Gils; Evelien M Bunnik; Brigitte D Boeser-Nunnink; Judith A Burger; Marijke Terlouw-Klein; Naomi Verwer; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

6.  Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1.

Authors:  Hua-Xin Liao; Chun-Yen Tsao; S Munir Alam; Mark Muldoon; Nathan Vandergrift; Ben-Jiang Ma; Xiaozhi Lu; Laura L Sutherland; Richard M Scearce; Cindy Bowman; Robert Parks; Haiyan Chen; Julie H Blinn; Alan Lapedes; Sydeaka Watson; Shi-Mao Xia; Andrew Foulger; Beatrice H Hahn; George M Shaw; Ron Swanstrom; David C Montefiori; Feng Gao; Barton F Haynes; Bette Korber
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

7.  A mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine development.

Authors:  Tim-Henrik Bruun; Katharina Mühlbauer; Thomas Benen; Alexander Kliche; Ralf Wagner
Journal:  PLoS One       Date:  2014-10-03       Impact factor: 3.240

8.  Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.

Authors:  Iliyana Mikell; Leonidas Stamatatos
Journal:  PLoS One       Date:  2012-11-13       Impact factor: 3.240

9.  Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.

Authors:  Sam Hoot; Andrew T McGuire; Kristen W Cohen; Roland K Strong; Lars Hangartner; Florian Klein; Ron Diskin; Johannes F Scheid; D Noah Sather; Dennis R Burton; Leonidas Stamatatos
Journal:  PLoS Pathog       Date:  2013-01-03       Impact factor: 6.823

10.  Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.

Authors:  Kristin M Narayan; Nitish Agrawal; Sean X Du; Janelle E Muranaka; Katherine Bauer; Daniel P Leaman; Pham Phung; Kay Limoli; Helen Chen; Rebecca I Boenig; Terri Wrin; Michael B Zwick; Robert G Whalen
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.